Novartis expands production of Pluvicto with addition of its largest, most advanced radioligand therapy manufacturing facility in Indianapolis

Novartis has expanded its production of Pluvicto by adding its biggest and most advanced radioligand therapy manufacturing facility in Indianapolis. The company aims to meet the growing demand for this innovative treatment. Novartis uses cookies for analytics, advertising, and to improve its site, and users agree to their use by continuing to use the site. The company’s Cookie Policy and Cookie Settings provide more information on this.

Source link